Stock Screener App

Frei -

Installieren

0.698

0.72% 0.005

Xilio Therapeutics Inc (XLO)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten

Xilio Therapeutics Executives Increase Holdings - TradingView

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World

Xilio Therapeutics Expands Authorized Shares at Annual Meeting - TipRanks

Xilio Therapeutics Appoints Akintunde Bello to Board of Directors - citybiz

Xilio Therapeutics appoints oncology veteran Akintunde Bello to board By Investing.com - Investing.com South Africa

Xilio Therapeutics expands board, elects new director - Investing.com Australia

Xilio Therapeutics expands board, elects new director By Investing.com - Investing.com South Africa

Xilio Therapeutics Expands Board with New Director - TipRanks

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Manila Times

Xilio Therapeutics appoints oncology veteran Akintunde Bello to board - Investing.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., To Its Board Of Directors - MarketScreener

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors - Nasdaq

Bristol Myers Squibb Oncology Leader Joins Xilio Board: Key Boost for Novel Cancer Immunotherapy Programs - Stock Titan

Leadership Experience 2025: Starbucks Rallies 14,000 North America Coffeehouse Leaders to Accelerate its 'Back to Starbucks' Strategy - The Globe and Mail

Uranium Royalty Corp. Announces U.S.$30 Million Bought Deal Financing - The Globe and Mail

Musk-Trump Messy Breakup Wipes Out $150B in TSLA Stock: What's Next? - The Globe and Mail

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire

Xilio Therapeutics Announces $50 Million Public Offering and Potential $150 Million in Total Gross Proceeds - Nasdaq

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire Inc.

Market Analysis: June 4th, 2025 - The Globe and Mail

International Resources Holding Enters into Agreement to Acquire Majority Interest in Alphamin Resources Corp. from Tremont Master Holdings - The Globe and Mail

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Biotech Startup Xilio Awards $194K Worth of Stock Options Under Nasdaq Compliance Plan - Stock Titan

Xilio Therapeutics Inc (NASDAQ: XLO) Is Down -26.69% Year-To-Date, But Analysts Find Room For A Price Rally - Stocksregister

Form 424B5 Xilio Therapeutics, Inc. - StreetInsider

Xilio Therapeutics announces public offering of warrants By Investing.com - Investing.com South Africa

Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial - MSN

Xilio Therapeutics tumbles after $50 mln equity offering - TradingView

Xilio Therapeutics (XLO) Launches Public Offering of Warrants | - GuruFocus

Xilio Therapeutics announces pricing of $50 million public offering - MSN

Xilio Therapeutics (XLO) Launches Public Offering of Warrants | XLO Stock News - GuruFocus

Xilio Therapeutics (XLO) Stock Dips Following Public Offering Announcement - GuruFocus

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering - The Manila Times

Xilio Therapeutics Secures $150M Potential Funding Through Strategic Warrant Offering for Cancer Therapies - Stock Titan

Xilio Therapeutics Announces Proposed Public Offering - marketscreener.com

Xilio Therapeutics (XLO) Launches Public Offering for Warrants | - GuruFocus

SEC Form 424B5 filed by Xilio Therapeutics Inc. - Quantisnow

Xilio Therapeutics drops on equity raise plans - TradingView

Xilio Therapeutics Presents Phase 2 Trial Data Update - TipRanks

Xilio Therapeutics announces public offering of warrants - Investing.com

Xilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C Warrants - Nasdaq

Immuno-Oncology Biotech Xilio Therapeutics Unveils Complex Public Offering With Multiple Warrant Series - Stock Titan

Xilio Therapeutics (XLO) Reveals Positive Phase 2 Trial Data for Cancer Treatment | XLO Stock News - GuruFocus

Xilio Therapeutics Announces Updated Phase 2 Data for - GlobeNewswire

Xilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal Cancer - Nasdaq

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - The Manila Times

Xilio Therapeutics Announces Updated Phase 2 Data For Vilastobart, A Tumor-Activated Anti-Ctla-4, In Combination With Atezolizumab In Patients With Metastatic Microsatellite Stable Colorectal Cancer - marketscreener.com

Breakthrough: New Immunotherapy Achieves 26% Response Rate in Hard-to-Treat Colorectal Cancer Patients - Stock Titan

Xilio Therapeutics Reports Q1 2025 Financial Results - TipRanks

Thinking Of Buying Xilio Therapeutics Inc (NASDAQ: XLO) Stock? Here Is What You Should Know - Stocksregister

Xilio Therapeutics (NASDAQ:XLO) Upgraded at Wall Street Zen - Defense World

GMAB

$20.30

0.68%

RPRX

$36.37

0.50%

SMMT

$24.55

8.53%

INSM

$97.80

0.45%

BNTX

$110.00

1.61%

ONC

$245.49

0.48%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters